<DOC>
	<DOCNO>NCT02743260</DOCNO>
	<brief_summary>The objective present study contribute establish vivo phenotyping procedure organic anionic transporter polypeptide 1B1 ( OATP1B1 ) , organic cation transporter 1 2 ( OCT1/2 ) , multidrug toxic compound extrusion transporter 1 2 , kidney splice variant ( MATE1/2K ) , organic anion transporter 1 3 ( OAT1/3 ) , p-glycoprotein ( P-gp ) transporter via cocktail approach . To end , marker substrate respective transporter administer single dos one period cocktail one period 24 healthy volunteer , phenotyping metric derive plasma urine concentration .</brief_summary>
	<brief_title>Drug Transporter Interaction Study PHENTRA_2015_KPUK</brief_title>
	<detailed_description>Blood sampling : - 0:15 h pre-dose , 0:15 , 0:30 , 0:45 , 1:00 , 1:20 , 1:40 , 2:00 , 2:20 , 2:40 , 3:00 , 3:30 , 4:00 , 5:00 , 6:00 , 8:00 , 12:00 , 16:00 , 24:00 hour post-dose Urine Sampling : Pre-dose , 0-4 hour , 4-8 hour , 8-12 hour , 12-16 hour , 16-24 hour Drug analysis : liquid chromatography - tandem mass spectrometry ( LC-MS/MS ) Pharmacokinetic Characteristics : Evaluation carry use standard noncompartmental characteristic include : area plasma concentration vs. time curve truncate time ( AUC0-t ) , area plasma concentration vs. time curve extrapolate infinity ( AUC0-∞ ) , peak plasma concentration ( Cmax ) , time occurrence Cmax ( tmax ) , apparent elimination half-life ( t½ ) , clearance bioavailability ( CL/F ) , renal clearance ( CLr ) renal secretion . The evaluation may complete compartmental population pharmacokinetic approach . Statistical evaluation : Pharmacokinetic characteristic compare cocktail administration vs. individual administration standard average bioequivalence assessment . Safety , tolerability : Adverse event , laboratory clinical parameter vital sign assess .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Caucasian Body mass index ( BMI ) inclusive 18.5 30 kg/m2 Willing capable confirm write consent prior enrolment ample information provide Normal finding medical history unless principal investigator considers abnormality clinically relevant . Considered healthy principal investigator basis extensive prestudy screen Standard healthy volunteer , include : Female subject : positive result pregnancy test Female subject : lactate woman Female subject : subject use agree use appropriate contraceptive method study define Note Guidance NonClinical Safety Studies Conduct Human Clinical Trials Pharmaceuticals ( CHMP/ICH/286/95 modification )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>phenotype</keyword>
	<keyword>transporter</keyword>
	<keyword>cocktail</keyword>
</DOC>